LONDON (Alliance News) - ValiRx PLC Thursday said its joint venture ValiSeek Ltd has received notification of a patent grant allowance from the New Zealand Patent Office.
ValiSeek is a joint venture with Tangent Reprofiling Ltd. It has received a patent grant for its US9072743, which covers both the formulation of its VAL401 treatment and its use for hormone-related cancers, including lung cancer, in New Zealand.
"This is the first non-US patent grant allowance received for the VAL401 project and as such, it provides an international validation of the programme to support world-wide commercialisation," said Chief Executive Officer Suzanne Dilly in a statement.
Shares in ValiRx were up 3.2% at 6.97 pence Thursday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
ValiRx (VAL)